Ambeed 大中华区 CN | ZH

中文 - ZH English - EN

Ambeed.cn

搜索

关键字搜索批量搜索

首页 收藏 购物车0
首页 /
抑制剂/激动剂
肿瘤
/
MAPK/ERK Pathway
肿瘤生长增殖和凋亡
/ MEK / Selumetinib

司美替尼 /Selumetinib {[allProObj[0].p_purity_real_show]}

货号：A351367 同义名： 司美替尼 (AZD6244) / AZD6244;ARRY-142886

Selumetinib(AZD6244) 是一种选择性、非ATP竞争性口服MEK1/2抑制剂，对MEK1的IC50为14 nM，并抑制ERK1/2的磷酸化。

Selumetinib 化学结构 CAS号：606143-52-6
Selumetinib 化学结构
CAS号：606143-52-6
Selumetinib 3D分子结构
CAS号：606143-52-6
Selumetinib 化学结构 CAS号：606143-52-6
Selumetinib 3D分子结构 CAS号：606143-52-6
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price) ]} 		{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 1周 咨询 - +
购物车0 收藏 询单

Selumetinib 纯度/质量文件 产品仅供科研

货号：A351367 标准纯度： {[allProObj[0].p_purity_real_show]}
批次查询： 批次纯度:

全球学术期刊中引用的产品

• ACS Appl. Nano Mater., 2025. Ambeed. [ A188026 ]
• Eur. J. Clin. Microbiol. Infect. Dis., 2025. Ambeed. [ A151161 ]
• JJC, 2025, 20(Special Issue)): 27-39. Ambeed. [ A713856 ]
• bioRxiv, 2025. Ambeed. [ A538667 , A714873 , A126729 , A126049 , A446054 ]
• Nature Communications, 2025, 16, 1871. Ambeed. [ A508148 ]
更多 >
产品名称 MEK ↓ MEK1 ↓ MEK1/2 ↓ MEK2 ↓ MEK5 ↓ 其他靶点 纯度
Honokiol ✔ 98%
Mirdametinib ++++

MEK, IC50: 0.33 nM

 		99%+
Binimetinib +++

MEK, IC50: 12 nM

 		99%+
BI-847325 ++

MEK1, IC50: 25 nM

 		+++

MEK2, IC50: 4 nM

 		99%+
U0126-EtOH +

MEK1, IC50: 0.07 μM

 		++

MEK2, IC50: 0.06 μM

 		98%
GDC-0623 ++++

MEK1, IC50: 0.13 nM

 		99%+
TAK-733 ++++

MEK1, IC50: 3.2 nM

 		99%+
Trametinib ++++

MEK1, IC50: 0.92 nM

 		++++

MEK2, IC50: 1.8 nM

 		99%+
Selumetinib +++

MEK1, IC50: 14 nM

MEK1, Kd: 99 nM

 		+

MEK2, Kd: 530 nM

 		99%+
CI-1040 ++

MEK1, IC50: 17 nM

 		++

MEK2, IC50: 17 nM

 		99%+
Myricetin ✔ 98%
Refametinib ++

MEK1, IC50: 19 nM

 		++

MEK2, IC50: 47 nM

 		99%+
Cobimetinib +++

MEK1, IC50: 4.2 nM

 		99%+
PD98059 +

MEK1, IC50: 2 μM

 		99%+
SL327 +

MEK1, IC50: 0.18 μM

 		+

MEK2, IC50: 0.22 μM

 		AP-1 98+%
PD318088 ✔ 99%
AZD8330 +++

MEK1/2, IC50: 7 nM

 		99%+
Pimasertib 98%
(E/Z)-BIX02189 ++++

MEK5, IC50: 1.5 nM

 		99%+
(E/Z)-BIX02188 +++

MEK5, IC50: 4.3 nM

 		99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Selumetinib 生物活性

靶点

  • MEK2

    MEK2, Kd:530 nM

  • MEK1

    MEK1, IC50:14 nM

    MEK1, Kd:99 nM
描述 The Ras-Raf-MEK pathway is overactive in many human cancers, such as melanoma and NSCLC. Selumetinib, also called as ARRY-142886 or AZD6244, is a potent and highly selective MEK1/2 inhibitor with IC50 of 14 nM (measured by the catalytic activation of purified His-MEK1 on ERK2). Selumetinib can inhibit the enzymatic activity of MEK1/2 but not the MEK1/2 phosphorylation by Raf. IC50 of Selumetinib to inhibit MEK1/2 phosphorylation on ERK1/2 in cell lines examed is less than 40 nM. In EGFR-overexpressed A431 cells, EGF-induced ERK1/2 phosphorylation can be inhibited by Selumetinib at the concentration < 10 μM in a dose-dependent manner, while no obvious inhibition can be observed in ERK5. In cell growth study, Selumetinib shows more potent in cell lines containing activating B-Raf and Ras mutations (HT-29, Malme-3M, MIA PaCa-2, SK-MEL-2, SK-MEL-28 cells, IC50 values ranging from 59 to 473 nM), while it had no effect on other cell lines examined, including BxPC3, BT474 and Malme-3 cells with no Raf/Ras-mutantion reported. 21-day administration of selumetinib orally, BID, can inhibit the tumour growth up to 70% at the concentration of 100 mg/kg in mice bearing HT-29 tumors and inhibition of phospho-ERK1/2 was seen[1]. Selumetinib is mainly used in the study of melanoma, NSCLC, Neurofibromatosis type 1 etc.[2].
作用机制 Molecular modeling data shows Selumetinib can bind to the allosteric inhibitor binding site in MEK1/2[1].

Selumetinib 细胞研究

细胞系 浓度 检测类型 检测时间 活性说明 数据源
human A101D cell Growth inhibition assay Inhibition of human A101D cell growth in a cell viability assay, IC50=240.33 nM. SANGER
human A375 cells Proliferation assay 72 h Antiproliferative activity against human A375 cells expressing BRAF V600E mutant after 72 hrs by Cell titer-glo assay, IC50=31 nM. 23474388
human A549 cell Growth inhibition assay Inhibition of human A549 cell growth in a cell viability assay, IC50=214.13 nM. SANGER
human AsPC-1 cell Growth inhibition assay Inhibition of human AsPC-1 cell growth in a cell viability assay, IC50=324.39 nM. SANGER

Selumetinib 动物研究

Dose Mice[3] (i.p.): min = 25 mg/kg, max = 100 mg/kg
Administration i.p.
Pharmacokinetics
Animal Nude mice[4]
Dose 10 mg/kg
Administration p.o.
Cmax 2977 ng/ml
T1/2 2.29 h
Tmax 1.0 h
AUC 17525 ng/(ml·h)
Vz/F 1.9 L/kg
Cl/F 0.6 L/(h·kg)

Selumetinib 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT00085787 Advanced Cancer Phase 1 Completed - United States, Colorado ... 展开 >> University of Colorado Cancer Center, Anschutz Cancer Center Aurora, Colorado, United States, 80010 United States, Minnesota Mayo Clinic Rochester Rochester, Minnesota, United States, 55905 United States, Pennsylvania Fox Chase Cancer Center Philadelphia, Pennsylvania, United States, 19111 收起 <<
NCT00780676 Breast Cancer Phase 2 Terminated(Closed early for fu... 展开 >>tility.) 收起 << - United States, Texas ... 展开 >> UT MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT02546661 Muscle Invasive Bladder Cancer Phase 1 Recruiting March 27, 2020 -

Selumetinib 参考文献

[1]Yeh TC, Marsh V, et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res. 2007 Mar 1;13(5):1576-83.

[2]Bernabé R, Patrao A, et al. Selumetinib in the treatment of non-small-cell lung cancer. Future Oncol. 2016 Nov;12(22):2545-2560.

[3]Bartholomeusz C, Oishi T, et al. MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model. Mol Cancer Ther. 2012 Feb;11(2):360-9.

[4]Denton CL, Gustafson DL, et al. Pharmacokinetics and pharmacodynamics of AZD6244 (ARRY-142886) in tumor-bearing nude mice. Cancer Chemother Pharmacol. 2011 Feb;67(2):349-60.

Selumetinib 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.18mL

0.44mL

0.22mL

10.92mL

2.18mL

1.09mL

21.85mL

4.37mL

2.18mL

Selumetinib 技术信息

CAS号606143-52-6
分子式C17H15BrClFN4O3
分子量 457.681
别名 司美替尼 (AZD6244) ;AZD6244;ARRY-142886;ARRY886;NSC 741O78;CL 1,040
运输蓝冰
存储条件

In solvent -20°C:3-6个月-80°C:12个月

Pure form Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
溶解方案

DMSO: 20 mg/mL(43.7 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议现用现配，当天使用； 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶
方案一
方案二
动物实验配方

4% DMSO+30% PEG 300+5% Tween 80+water 5 mg/mL

Tags: Selumetinib | 606143-52-6 | AZD6244 | ARRY-142886 | AZD 6244 | AZD-6244 | ARRY142886 | ARRY 142886 | ARRY-142886 | MEK1/2 Inhibitor | MAPK/ERK Pathway | Apoptosis | MEK | Apoptosis | 仅供科研使用 | AmBeed-信号通路专用抑制剂 | Selumetinib 纯度/质量文件 | Selumetinib 亚型比较 | Selumetinib 生物活性 | Selumetinib 细胞研究 | Selumetinib 动物研究 | Selumetinib 临床数据 | Selumetinib 参考文献 | Selumetinib 实验方案 | Selumetinib 技术信息

Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
    • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质用途提供服务。

    尊敬的 Ambeed 客户您好，
    请您选择所在区域，我们将转接对应客服为您服务！

    热门区域

    A

    B

    C

    F

    G

    H

    J

    L

    N

    Q

    S

    T

    X

    Y

    Z

    热 A B C F G H J L N Q S T X Y Z